MYMD

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. It is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. Its lead clinical candidate, MYMD-1, is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is an orally available TNF-a inhibitor that is being developed to treat age-related illnesses, such as frailty and sarcopenia. Its second therapeutic candidate, Supera-CBD, is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme (MAO) type B.